{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:55:11Z","timestamp":1776142511951,"version":"3.50.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) complicated by portal vein tumor thrombosis (PVTT) is associated with limited therapeutic options and poor survival. Immune checkpoint inhibitors, especially when combined with tyrosine kinase inhibitors (TKIs), locoregional therapies, or radiotherapy, are reshaping the management of advanced HCC; however, the optimal way to integrate these modalities, particularly in patients with vascular invasion and low programmed death-ligand 1 (PD-L1) expression, remains uncertain. Herein, we describe a 52-year-old man with advanced HCC complicated by PVTT who initially received transarterial chemoembolization (TACE), hepatic resection, and adjuvant lenvatinib but later developed postoperative recurrent disease, including a right perirenal lesion and a synchronous right subpleural metastatic lesion. He then achieved a durable complete response and long-term survival with an immunotherapy-centered regimen combining radiotherapy, lenvatinib, and tislelizumab. This case suggests that an immunotherapy-based multimodal regimen integrating TACE, surgery, TKI therapy, radiotherapy, and programmed cell death protein 1 (PD-1) blockade can achieve deep and durable remission in selected patients with advanced HCC and low PD-L1 expression.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1746806","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:20:58Z","timestamp":1776140458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term survival after multimodal therapy for advanced hepatocellular carcinoma: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Danxin","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Oncology, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyue","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunli","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bangchun","family":"Ming","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tieyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35278","article-title":"The globocan 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32411","article-title":"Dynamic risk profiling of hcc recurrence after curative intent liver resection","volume":"76","author":"Ivanics","year":"2022","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08452-3","article-title":"Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and Beyond the Barcelona Clinic Liver Cancer Criteria","volume":"27","author":"Tsilimigras","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00434-5","article-title":"Precision surgery for hepatocellular carcinoma","volume":"10","author":"Magyar","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i32.7289","article-title":"Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016","volume":"22","author":"Chan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-012-1188-0","article-title":"Surgical resection for advanced hepatocellular carcinoma according to barcelona clinic liver cancer (Bclc) staging","volume":"138","author":"Yang","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (Hcc) from the esmo clinical practice guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Easl clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000549355","article-title":"Rechallenge with immune checkpoint inhibitors in patients with hepatocellular carcinoma: A narrative review","author":"Li","year":"2025","journal-title":"Liver Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1159\/000546574","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000546899","article-title":"Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study","volume":"15","author":"Kudo","year":"2025","journal-title":"Liver Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (Cares-310): A randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117343","article-title":"Recent advancements in the small-molecule drugs for hepatocellular carcinoma (Hcc): structure-activity relationships, pharmacological activities, and the clinical trials","volume":"179","author":"Deng","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (Leap-002): A randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10480-y","article-title":"Real-world efficacy and prognostic factors of lenvatinib plus pd-1 inhibitors in 378 unresectable hepatocellular carcinoma patients","volume":"17","author":"Yang","year":"2023","journal-title":"Hepatol Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01157","article-title":"Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: A potential synergistic treatment strategy","volume":"9","author":"Chiang","year":"2019","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1594577","article-title":"Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: A real-world study of 108 patients","volume":"16","author":"Zhai","year":"2025","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2021","journal-title":"J Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000523997","article-title":"Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Liver Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15130","article-title":"Treatment and the prognosis of hepatocellular carcinoma in asia","volume":"42","author":"Torimura","year":"2022","journal-title":"Liver Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000000710","article-title":"Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis","volume":"261","author":"Tabrizian","year":"2015","journal-title":"Ann Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11454-y","article-title":"Clinical features of recurrence after hepatic resection for early-stage hepatocellular carcinoma and long-term survival outcomes of patients with recurrence: A multi-institutional analysis","volume":"29","author":"Yao","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S352480","article-title":"Postoperative adjuvant transarterial chemoembolization plus tyrosine kinase inhibitor for hepatocellular carcinoma: A multicentre retrospective study","volume":"9","author":"Lin","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.807102","article-title":"Efficacy of sorafenib combined with immunotherapy following transarterial chemoembolization for advanced hepatocellular carcinoma: A propensity score analysis","volume":"12","author":"Qin","year":"2022","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466","article-title":"Aasld practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1038\/s41467-024-47420-3","article-title":"Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the notable-hcc phase 1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (Imbrave050): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e430028","DOI":"10.1200\/EDBK_430028","article-title":"Updates on systemic therapy for hepatocellular carcinoma","volume":"44","author":"Ntellas","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000527175","article-title":"Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (Rationale-208): A multicenter, non-randomized, open-label, phase 2 trial","volume":"12","author":"Ren","year":"2022","journal-title":"Liver Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1002\/mco2.474","article-title":"Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy","volume":"5","author":"Luo","year":"2024","journal-title":"MedComm (2020)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12885-025-14092-1","article-title":"Comparative Efficacy of Tislelizumab Plus Lenvatinib and Tislelizumab Alone against Advanced Hepatocellular Carcinoma after Lenvatinib Failure: A Real-World Study","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.11.024","article-title":"Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable stage III nsclc (Pacific)","volume":"151","author":"Faivre-Finn","year":"2021","journal-title":"Lung Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent pd-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab129","article-title":"Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of airo","volume":"23","author":"Scoccianti","year":"2021","journal-title":"Neuro Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","article-title":"Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma","volume":"23","author":"Chan","year":"2024","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"Pd-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (Keynote-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","article-title":"Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, tkis, and chemotherapy","volume":"18","author":"Dai","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0558","article-title":"Combination of tmb and cna stratifies prognostic and predictive responses to immunotherapy across metastatic cancer","volume":"25","author":"Liu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001163","article-title":"Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy","volume":"81","author":"Scheiner","year":"2025","journal-title":"Hepatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1746806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:20:59Z","timestamp":1776140459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1746806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2026.1746806"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1746806","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1746806"}}